|Day's range||0.8600 - 1.1000|
Beam Therapeutics (NASDAQ: BEAM) is exactly the kind of innovative biotech business that maverick growth stock investor Cathie Wood craves. Most recently, between April 27 and May 8, Wood bought shares of Beam Therapeutics five times, and more purchases are probably on the way, given her penchant for adding to her position multiple times per month since early 2021. Beam Therapeutics is a gene-editing biotech.
Cathie Wood looks for stocks that are leading innovators. But the stocks that fit that mold aren't always leaders when it comes to delivering huge returns over the short term. On the contrary, quite a few of the stocks in Wood's Ark Invest portfolios have been big losers.
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 2.21% and 67.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
If there's one word you could use to describe the kinds of stocks that Cathie Wood buys, it would be "innovative." In fact, three of her ARK Invest exchange-traded funds (ETFs) include the word "innovation" in their names. Wood's flagship ARK Innovation ETF has loaded up in recent weeks on Beam Therapeutics (NASDAQ: BEAM).
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Beam Therapeutics Inc. ( NASDAQ:BEAM ) shareholders will have a reason to smile today, with the analysts making...
Three Motley Fool contributors were asked to select stocks to buy in March that truly are game changers. Here's why they picked Beam Therapeutics (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP), and Vertex Pharmaceuticals (NASDAQ: VRTX). Keith Speights (Beam Therapeutics): Base editing is an approach to editing genes invented in 2016 by a team led by David Liu.
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 59.09% and 69.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Gene-editing biotech companies are showing the potential to cure diseases. The Food and Drug Administration (FDA) could approve the first CRISPR gene-editing therapy this year -- exa-cel, developed by CRISPR Therapeutics and Vertex Pharmaceuticals -- to treat severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TBT), a blood disorder associated with anemia. Two others to watch for with solid long-term prospects are Beam Therapeutics (NASDAQ: BEAM) and Intellia Therapeutics (NASDAQ: NTLA).
Cathie Wood is roaring back. Her flagship ARK Innovation ETF (NYSEMKT: ARKK) plunged 67% last year. But so far in 2023, the exchange-traded fund is up nearly 40%. This impressive performance could be just the warm-up.
Beam Therapeutics Inc. ( NASDAQ:BEAM ) shareholders should be happy to see the share price up 16% in the last month...
The Nasdaq Composite has surged over 11% so far this month as growth stocks retake center stage. Shopify (NYSE: SHOP), the Vanguard Growth ETF (NYSEMKT: VUG), Nio (NYSE: NIO), Beam Therapeutics (NASDAQ: BEAM), and Roku (NASDAQ: ROKU) have that kind of potential. Here's what makes each company a great buy now, according to five Motley Fool contributors.
Three Motley Fool contributors were asked to identify great growth stocks down 20% or more to buy now. Here's why they chose Beam Therapeutics (NASDAQ: BEAM), Maravai LifeSciences (NASDAQ: MRVI), and Novavax (NASDAQ: NVAX). Keith Speights (Beam Therapeutics): Beam Therapeutics was flying high in the early part of 2021.
Is the stock market in store for another bull market? Absolutely, undoubtedly yes. Will it take place in 2023? That remains to be seen. But there's no question that sooner or later stocks will once again begin a sustained period of positive momentum.
Country music singer Garth Brooks once said that he had more money than his great-grandchildren would be able to spend. Here are three stocks that could create lasting generational wealth. If you haven't heard of base editing, just give it some time.
Beam Therapeutics is different from many CRISPR-editing biotechs in that it uses ex-vivo base cell editing instead of nuclease cell editing. Beam stock is down more than 48% so far this year, but the company has a growing pipeline that shows promise. Its lead therapy is BEAM-101 to treat various blood diseases, including sickle cell disease (SCD) and beta thalassemia.
Every investor in Beam Therapeutics Inc. ( NASDAQ:BEAM ) should be aware of the most powerful shareholder groups. The...
The FDA lifts the clinical hold on BEAM's investigational new drug application for BEAM-201 to treat relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma. Stock up.
Beam Therapeutics ( NASDAQ:BEAM ) Third Quarter 2022 Results Key Financial Results Revenue: US$15.8m (up by US$15.0m...
Beam's decision not to move forward with sickle cell treatment BEAM-102 isn't sitting well with investors today.
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of -20% and 51.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog.
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, which have the potential to gain from their promising gene therapy pipeline candidates.
Shares of the clinical-stage base-editing company Beam Therapeutics (NASDAQ: BEAM) stormed higher through the first four days of trading this week. Beam's sizable uptick seems to simply be a rebound following last week's 23% drop in its share price. Clinical-stage biotech stocks have been extremely volatile this year, thanks to rising interest rates, geopolitical turmoil, and investors' general aversion to risk right now.
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 5.56% and 26.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?